Axovant Gene Therapies (NASDAQ:AXGT) had its target price raised by JMP Securities from $8.00 to $28.00 in a report published on Thursday, June 6th, The Fly reports. JMP Securities currently has an outperform rating on the stock.
Several other equities research analysts have also recently commented on the company. Cowen reaffirmed a hold rating on shares of Axovant Gene Therapies in a research report on Wednesday, May 1st. Chardan Capital raised Axovant Gene Therapies from a neutral rating to a buy rating and set a $32.00 target price on the stock in a research report on Monday, March 11th. Guggenheim began coverage on Axovant Gene Therapies in a research report on Friday, February 15th. They issued a buy rating and a $56.00 target price on the stock. HC Wainwright reissued a buy rating and issued a $56.00 target price on shares of Axovant Gene Therapies in a research report on Tuesday, March 12th. Finally, ValuEngine raised Axovant Gene Therapies from a buy rating to a strong-buy rating in a research report on Thursday, May 9th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $28.76.
Shares of Axovant Gene Therapies stock traded up $0.04 during trading on Thursday, hitting $6.23. 306,982 shares of the company’s stock traded hands, compared to its average volume of 1,536,163. The company has a quick ratio of 2.63, a current ratio of 2.63 and a debt-to-equity ratio of 0.41. Axovant Gene Therapies has a 1 year low of $3.81 and a 1 year high of $24.32. The stock has a market cap of $141.01 million, a PE ratio of -0.78 and a beta of 1.39. The stock has a 50-day simple moving average of $6.50.
In other news, CEO Pavan Cheruvu bought 7,500 shares of the company’s stock in a transaction on Friday, June 14th. The shares were acquired at an average cost of $5.21 per share, with a total value of $39,075.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.20% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of AXGT. Sphera Funds Management LTD. bought a new stake in shares of Axovant Gene Therapies in the 1st quarter valued at $6,794,000. Marshall Wace LLP bought a new stake in shares of Axovant Gene Therapies in the 1st quarter valued at $272,000. Finally, Primecap Management Co. CA bought a new stake in shares of Axovant Gene Therapies in the 1st quarter valued at $1,400,000.
Axovant Gene Therapies Company Profile
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.